An Evaluation of Hepatitis B Virus Diagnostic Methods and Responses to Antiretroviral Therapy among HIV-Infected Women in Thailand
oleh: Philip James Peters MD, Janet M. McNicholl MD, Boonyos Raengsakulrach PhD, Punneeporn Wasinrapee MS, Famui Mueanpai BS, Winai Ratanasuwan MD, Poj Intalapaporn MD, Jan Drobeniuc MD, PhD, Sumathi Ramachandran PhD, Hong Thai PhD, Guo-Liang Xia MD, MPH, Saleem Kamili PhD, Yury Khudyakov PhD, Paul J. Weidle PharmD, MPH, Chong Gee Teo MD, PhD, Michelle S. McConnell MD
| Format: | Article |
|---|---|
| Diterbitkan: | SAGE Publishing 2013-09-01 |
Deskripsi
Coinfection with HIV and hepatitis B virus (HBV) is common in resource-limited settings but is frequently not diagnosed. The authors retrospectively tested specimens for HBV in HIV-infected Thai women who had participated in an antiretroviral therapy (ART) clinical study. A substantial proportion (27 of 211; 13%) of HIV-infected women were HBV coinfected. Among HIV/HBV-coinfected women, the authors observed similar rates of antiretroviral-associated liver toxicity (despite nevirapine [NVP] use) and CD4 count reconstitution as observed in HIV-monoinfected women. Hepatitis B surface antigen (HBsAg) screening detected the majority (81%) of HBV coinfections, including all 5 HBV-coinfected women who did not suppress HBV despite 48 weeks of lamivudine (3TC)-containing ART and could be used to tailor ART for patients diagnosed with HBV coinfection in accordance with World Health Organization guidelines. Although HBsAg screening did not diagnose 5 occult HBV coinfections, these women achieved HBV suppression on 3TC-containing ART, suggesting that not detecting occult HBV coinfection would have limited clinical impact.